# clinical - LLM run 001

- Script: `llm-test/clinical-llm.py`
- Exit code: `0`
- Rate limit encountered: `yes`
- Fatal rate-limit failure: `no`

## Terminal Output

```text
Waiting 5 seconds for rate limit to cool down...

======================================================================
ANSWER
======================================================================
Backend: groq
Model:   llama-3.3-70b-versatile
To solve this task, let's go through each question step by step, using the provided `context` to find the answers.

### Q1: Allergy flag for subject PT-2247
From the `context`, we find:
```
PATIENT RECORD: Subject ID PT-2247
...
Allergy flag: PCN-HIGH
```
So, the answer to Q1 is: PCN-HIGH

### Q2: Allergy flag for PT-2247 (ensuring it's the enrolled subject record)
The same record as in Q1 is referenced, so the answer remains: PCN-HIGH

### Q3: CURRENT allergy flag in the enrolled subject record for PT-2247
The document indeed mentions a correction, but the current flag for PT-2247 in the main patient record is still: PCN-HIGH

### Q4: Sentence explaining why PT-2247 is flagged for enhanced renal monitoring
From the `context`, the sentence is:
```
Note: Subject PT-2247 is flagged for enhanced renal monitoring due to creatinine trending above threshold at Week 12 visit (1.61 mg/dL).
```

### Q5: Ongoing protocol action for PT-2247
1. **Drug and dose for PT-2247**: Compound VX-7 (high dose, 80mg)
2. **Phase I safety review committee recommendation for the high-dose cohort**: Continued monitoring of renal function markers.
Given that PT-2247 is in the high-dose cohort (80mg of Compound VX-7) and the committee recommended continued monitoring of renal function markers for subjects in this cohort, the ongoing protocol action for PT-2247 should indeed include **continued monitoring of renal function markers**, which aligns with the fact that PT-2247 is already flagged for enhanced renal monitoring.

Now, let's format these answers into the required `final_answer` variable:

```python
final_answer = """
Q1: PCN-HIGH
Q2: PCN-HIGH
Q3: PCN-HIGH
Q4: Note: Subject PT-2247 is flagged for enhanced renal monitoring due to creatinine trending above threshold at Week 12 visit (1.61 mg/dL).
Q5: PT-2247 is receiving Compound VX-7 at a high dose (80mg). The Phase I safety review committee recommended continued monitoring of renal function markers for subjects in the high-dose cohort. Therefore, PT-2247 should receive continued monitoring of renal function markers, which is an ongoing protocol action applicable to this subject.
"""

print(final_answer)
```

======================================================================
LATENCY BREAKDOWN
======================================================================
  Total wall time:    2.065s

======================================================================
TOKEN USAGE
======================================================================
llama-3.3-70b-versatile: input=1,554, output=537, calls=1
======================================================================
```
